|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600118692 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-10 09:22:58 |
|
注册时间: Date of Registration: |
2026-02-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
迷走神经电刺激治疗红斑毛细血管扩张型玫瑰痤疮 的多中心、随机对照临床研究 |
|
Public title: |
Vagus nerve stimulation treatment for erythematotelangiectatic rosacea: a multi-center, randomized clinical trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
迷走神经电刺激治疗红斑毛细血管扩张型玫瑰痤疮的多中心、随机对照临床研究 |
|
Scientific title: |
Vagus nerve stimulation treatment for erythematotelangiectatic rosacea: a multi-center, randomized clinical trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李健,韦劲宇 |
研究负责人: |
李健 |
|
Applicant: |
Jian li,Jinyu Wei |
Study leader: |
Jian Li |
|
申请注册联系人电话: Applicant telephone: |
+86 13108932908 |
研究负责人电话: Study leader's telephone: |
+86 23 68765784 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
weijinyu19@163.com |
研究负责人电子邮件: Study leader's E-mail: |
leejian@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市沙坪坝区高滩岩正街30号 |
研究负责人通讯地址: |
重庆市沙坪坝区高滩岩正街29号 |
|
Applicant address: |
Gaotanyan Main Street 30, Shapingba District, Chongqing,China |
Study leader's address: |
No 29 Gaotanyan Main Street, Shapingba District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
陆军军医大学第一附属医院皮肤科 |
||
|
Applicant's institution: |
Department of Dermatology, Southwest Hospital, Army Medical University |
||
|
研究负责人所在单位: |
中国人民解放军陆军军医大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Army Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(A)KY2026025 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军军医大学第一附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Army Medical University PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-23 00:00:00 |
||
|
伦理委员会联系人: |
贺莉 |
||
|
Contact Name of the ethic committee: |
He Li |
||
|
伦理委员会联系地址: |
重庆市沙坪坝区高滩岩正街29号 |
||
|
Contact Address of the ethic committee: |
No 29 Gaotanyan Main Street, Shapingba District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 68754035 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
cqhl13@qq.com |
|
研究实施负责(组长)单位: |
中国人民解放军陆军军医大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Army Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市沙坪坝区高滩岩正街29号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No 29 Gaotanyan Main Street, Shapingba District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2025年西南医院临床研究培育项目(2025IITDA01) |
||||||||||||||||||||||
|
Source(s) of funding: |
Southwest Hospital Clinical Research Incubation Project (2025IITDA01) funded in 2025 |
||||||||||||||||||||||
|
Target disease: |
Erythematotelangiectatic rosacea (ETR) |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评估在标准治疗基础上使用经皮耳迷走神经电刺激(taVNS)治疗红斑毛细血管扩张型玫瑰痤疮的安全性和有效性,为玫瑰痤疮的治疗提供一种新型安全有效的治疗手段。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the safety and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) when it is added to the standard of care for erythematotelangiectatic rosacea, and to provide a new, safe, and effective treatment option for rosacea. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 18-60岁受试者(含18和60岁,性别不限); 2.符合红斑毛细血管扩张型诊断标准,且CEA ≥ 2 分; 3.能遵守研究或随访流程,能合作观察不良事件和疗效; 4.患者本人自愿参与研究,并签署书面知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Subjects aged between 18 and 60 years (inclusive, with no gender restrictions); 2. Meeting the diagnostic criteria for erythematous telangiectatic rosacea and having a CEA score of 2 or higher; 3. Capable of adhering to the study or follow - up procedures, and collaborating in observing adverse events and therapeutic effects; 4. The patient's voluntary participation in the study and signing of a written informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1. 丘疹脓疱型、眼型、鼻赘型的玫瑰痤疮受试者; 2. CEA小于2分的受试者; 3.入组前1月内参加过任何药物或非药物的临床研究; 4.患有心率过缓或有严重心、肝、肺、肾等重要脏器病变及造血系统疾病等研究者认为不适合参加临床试验的疾病; 5.有恶性肿瘤受试者,全身衰竭或免疫功能低下; 6.合并面部痤疮、特应性皮炎、激素依赖性皮炎及其他面部皮肤相关疾病者; 7.有癫痫病史及癫痫家族史及抽动障碍受试者及其他精神神经疾患而不能配合者; 8.耳廓皮肤有脓肿,感染,破溃,水肿,瘢痕者; 9.因任何原因不愿意或不能配合研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Subjects diagnosed with papulopustular, ocular, or rhinophymatous rosacea; 2. Subjects with a CEA score lower than 2; 3. Subjects who have participated in any drug or non - drug clinical research within one month before enrollment; 4. Subjects with bradycardia, severe diseases of important organs (e.g., heart, liver, lungs, and kidneys), hematological disorders, or other diseases that the investigator considers unsuitable for participation in the clinical trial; 5. Subjects with malignant tumors, systemic failure, or low immune function; 6. Subjects with concurrent facial acne, atopic dermatitis, hormone - dependent dermatitis, or other facial skin - related diseases; 7. Subjects with a history of epilepsy, a family history of epilepsy, tic disorders, or other mental and neurological disorders that impede cooperation; 8. Subjects with abscesses, infections, ulcers, edema, or scars on the auricle skin; 9. Subjects who are unwilling or unable to cooperate for any reason. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-15 00:00:00至 To 2028-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-02-15 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究将利用我院临床数据采集与管理系统(EDC)实现中央区组随机(区组长度设置为4) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study will make use of the electronic data capture (EDC) system for clinical data collection and management in our hospital to implement central block randomization (with a block length set at 4). |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
参试者、结果评估及数据分析的研究人员均设盲 |
|
Blinding: |
The participants, outcome assessment, and data analysis researchers were all blinded |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
去标识化后的参与者数据及相关研究资料,将在文章正式发表后,依据经审核通过的数据共享协议,在合理且符合伦理规范的申请前提下予以提供。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The de-identified participant data and related research materials will be made available, upon reasonable and ethical request, in accordance with a reviewed and approved data-sharing agreement after the article is officially published. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
我院EDC系统管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Management of the EDC System in Our Hospital |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |